Everett Harris & Co. CA cut its position in shares of Quest Diagnostics Inc (NYSE:DGX) by 1.1% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 7,427 shares of the medical research company’s stock after selling 80 shares during the period. Everett Harris & Co. CA’s holdings in Quest Diagnostics were worth $846,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. Ellevest Inc. lifted its holdings in Quest Diagnostics by 16.6% in the 2nd quarter. Ellevest Inc. now owns 618 shares of the medical research company’s stock valued at $70,000 after purchasing an additional 88 shares in the last quarter. River Wealth Advisors LLC raised its position in Quest Diagnostics by 2.9% in the first quarter. River Wealth Advisors LLC now owns 3,859 shares of the medical research company’s stock worth $310,000 after purchasing an additional 110 shares in the last quarter. Whittier Trust Co. lifted its stake in Quest Diagnostics by 4.0% during the first quarter. Whittier Trust Co. now owns 3,049 shares of the medical research company’s stock worth $244,000 after purchasing an additional 117 shares during the period. BKD Wealth Advisors LLC lifted its stake in Quest Diagnostics by 4.6% during the second quarter. BKD Wealth Advisors LLC now owns 2,644 shares of the medical research company’s stock worth $301,000 after purchasing an additional 117 shares during the period. Finally, HighPoint Advisor Group LLC boosted its holdings in Quest Diagnostics by 3.9% during the first quarter. HighPoint Advisor Group LLC now owns 3,460 shares of the medical research company’s stock valued at $368,000 after purchasing an additional 129 shares in the last quarter. Institutional investors own 88.88% of the company’s stock.

Shares of DGX opened at $127.07 on Friday. Quest Diagnostics Inc has a 52-week low of $73.02 and a 52-week high of $131.81. The company has a quick ratio of 1.21, a current ratio of 1.29 and a debt-to-equity ratio of 0.68. The stock has a fifty day simple moving average of $117.08 and a two-hundred day simple moving average of $107.37. The company has a market capitalization of $17.07 billion, a PE ratio of 23.06, a price-to-earnings-growth ratio of 0.95 and a beta of 1.38.

Quest Diagnostics (NYSE:DGX) last posted its earnings results on Thursday, July 23rd. The medical research company reported $1.42 EPS for the quarter, beating the Zacks’ consensus estimate of $1.41 by $0.01. The company had revenue of $1.83 billion for the quarter, compared to the consensus estimate of $1.81 billion. Quest Diagnostics had a return on equity of 13.78% and a net margin of 9.99%. The company’s revenue for the quarter was down 6.3% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.73 earnings per share. As a group, equities analysts anticipate that Quest Diagnostics Inc will post 8.42 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which was paid on Wednesday, July 22nd. Shareholders of record on Wednesday, July 8th were paid a dividend of $0.56 per share. This represents a $2.24 annualized dividend and a yield of 1.76%. The ex-dividend date of this dividend was Tuesday, July 7th. Quest Diagnostics’s dividend payout ratio (DPR) is presently 34.15%.

Several analysts recently commented on the company. Barclays boosted their price target on Quest Diagnostics from $93.00 to $99.00 and gave the company an “equal weight” rating in a research note on Thursday, April 23rd. UBS Group raised their price target on Quest Diagnostics from $106.00 to $111.00 and gave the company a “neutral” rating in a report on Tuesday, May 5th. BofA Securities upgraded Quest Diagnostics from a “neutral” rating to a “buy” rating and set a $142.00 target price on the stock in a report on Tuesday, July 14th. Mizuho lifted their price target on Quest Diagnostics from $114.00 to $144.00 and gave the company a “buy” rating in a report on Friday, July 24th. Finally, Deutsche Bank increased their price objective on shares of Quest Diagnostics from $140.00 to $150.00 and gave the stock a “buy” rating in a report on Friday, July 24th. Eleven investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $124.84.

Quest Diagnostics Company Profile

Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic testing information and services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.

Featured Article: How does a security become overbought?

Want to see what other hedge funds are holding DGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Quest Diagnostics Inc (NYSE:DGX).

Institutional Ownership by Quarter for Quest Diagnostics (NYSE:DGX)

Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.